Keynote: Dr. Allyson Berent (FAST) - How Parents Can Drive Drug Development for Rare Disease

  Рет қаралды 318

FOXG1 Research Foundation

FOXG1 Research Foundation

Жыл бұрын

The Keynote speaker at the FOXG1 Syndrome Science Symposium and Parents Conference was the incredibly brilliant and inspiring Allyson Berent, who the FRF calls "our North star."
Her presentation is titled: How Parents Can Drive Drug Development for Rare Disease: From impossible to possible for Angelman syndrome .
She is the example of a rare disease parent taking charge to make a difference, and she is making a true and exciting difference.
Bio:
In 2014 Dr. Berent’s daughter was diagnosed with a rare non-degenerative neurogenetic disorder called Angelman syndrome. In October of 2015 she joined the Board of Directors as a Scientific Director for the Foundation for Angelman Syndrome Therapeutics (FAST), and in March of 2016 became the Chief Science Officer for the Foundation.
Dr. Berent helped to spearhead the development of a pre-competitive biomarker and outcome measure consortium in order to bring patient focused outcome measures forward for human clinical trials (Angelman Syndrome Biomarker and Outcome Measure Consortium-ABOM) and now serves as the Director of this consortium.
Dr. Berent Co-Founded the International Angelman Syndrome Research Council (INSYNC-AS). Through FAST, Dr. Berent collaborated with a consortium of scientists to encourage translational research opportunities, in order to help bring novel genetic therapies forward toward human clinical trials. Through this work, with the foundation, Dr. Berent co-founded GeneTx Biotherapeutics, a company singularly focused to advance an antisense oligonucleotide (ASO) therapy through IND enabling studies and a phase 1/2 clinical trial. Dr. Berent currently serves as the Chief Operating Officer of GeneTx Biotherapeutics, who partnered with Ultragenyx Pharmaceuticals in August of 2019. This program was acquired by Ultragenyx in 2022. The Phase 1/2 clinical trial started enrolling patients in February 2020 as the first intrathecally delivered ASO for Angelman syndrome, a study of safety and tolerability of GTX-102.
-
Help cure FOXG1 syndrome: foxg1research.org/donate

Пікірлер
FOXG1 Research Foundation - Science Q&A June 2024
1:04:40
FOXG1 Research Foundation
Рет қаралды 292
Василиса наняла личного массажиста 😂 #shorts
00:22
Денис Кукояка
Рет қаралды 9 МЛН
ROCK PAPER SCISSOR! (55 MLN SUBS!) feat @PANDAGIRLOFFICIAL #shorts
00:31
He sees meat everywhere 😄🥩
00:11
AngLova
Рет қаралды 9 МЛН
Did you believe it was real? #tiktok
00:25
Анастасия Тарасова
Рет қаралды 12 МЛН
FOXG1 Syndrome Clinical Findings w/ Elli Brimble - The FOXG1 Conference 2022
37:53
How To Tell what  Mania and Hypomania Really Look like
14:06
Dr. Tracey Marks
Рет қаралды 780 М.
Navigating Hospitalizations: FOXG1 Parents Support Webinar
51:34
FOXG1 Research Foundation
Рет қаралды 82
8 Unexpected Ways We Self-Harm & How to Stop
23:06
Kati Morton
Рет қаралды 327 М.
Cognitive Behavioral Therapy Exercises (FEEL Better!)
12:36
Barbara Heffernan
Рет қаралды 959 М.
FOXG1 Research Foundation: Six Years of Progress
16:21
FOXG1 Research Foundation
Рет қаралды 131
Sustainability in Action webinar: Strategic planning budgeting and forecasting
49:35
Accounting for Sustainability (A4S)
Рет қаралды 107
Highlights from the 2022 FOXG1 Syndrome Parents Conference!
8:02
FOXG1 Research Foundation
Рет қаралды 372
Can you self-diagnose mental illness accurately?
37:53
Kati Morton
Рет қаралды 8 М.
Василиса наняла личного массажиста 😂 #shorts
00:22
Денис Кукояка
Рет қаралды 9 МЛН